Senores Pharmaceuticals Ltd.

Industry:

Pharmaceuticals & Drugs

Issue Details

  • Open Date

    20 Dec 2024
  • Close Date

    24 Dec 2024
  • Size (in Crs.)

    317.49 - 333.71

  • Size (Shares)

    -
  • Listing On

    NSE

Issue Terms

  • Price Range

    -19
  • Lot Size

    38

  • Type

    Book building

  • Face Value

    10

  • Market Lot

    1

Objective of the Issue

1. Funding the capital expenditure requirements by investment in of one of our Subsidiaries, Havix Group, Inc. d/b/a Aavis Pharmaceuticals (“Havix”), for setting up a manufacturing facility for the production of sterile injections in our Atlanta Facility;2. Re-payment/pre-payment, in full or in part, of certain borrowings availed by our Company and our Subsidiaries, namely, Havix, Ratnatris Pharmaceutical Private Limited (“Ratnatris”) and Senores Pharmaceuticals Inc. (“SPI”);3. Funding the working capital requirements of our Company and our Subsidiaries, namely, SPI and Ratnatris; and4. Funding inorganic growth through acquisition and other strategic initiatives and general corporate purposes.

Description

We are a global research driven pharmaceutical company engaged in developing and manufacturing a wide range of pharmaceutical products predominantly for the Regulated Markets across various therapeutic areas and dosage forms, with a presence in Emerging Markets. Our strength lies in identifying, developing and manufacturing a diverse range of specialty, underpenetrated and complex pharmaceutical products establishing us as a preferred partner to certain customers. Through data analytics, research, market asses...  Show More

Address

1101 To 1103, 11th Floor, South Tower , One 42 Opp. Jayantilal Park , Ambali Bopal Road

Ahmedabad

380054

State

Gujarat

Phone No.

079-29999857

Website

www. senorespharma.com

Promoter Holding

Promoters:

Ashokkumar Vijaysinh Barot, Swapnil Jatinbhai Shah

Total Share Capital

22176079

Offered to Public

-

% Promoter's Holding (Pre-Issue)  

66.66

% Promoter's Holding (Post-Issue)  

-

Shares on offer

Total Share Offer

22176079

Of above offred to public

-

Post Issue shares

NA

Post Issue Promoters

-

Lead Managers to the Issue:

Ambit Pvt Ltd., Equirus Capital Pvt Ltd, Nuvama Wealth Management Ltd.

Registrar Details

Registrar Name:

Link Intime India Pvt Ltd.

Address

C 101, 247 Park , LBS Marg , Vikhroli (West) , Mumbai

400083

Phone No.

-

Email

-

Website

-

Fax

-

Prudent Corporate Advisory Services Ltd.
"Prudent House", Panjrapole Cross Road,
Nr. Polytechnic, Ambawadi,
Ahmedabad - 380 015, Gujarat, India.
For Queries:
[email protected]
1800 419 5051 (Toll Free)
Compliance Officer:
Mrs. Rima Patel
[email protected]
(079) 40209600
Social Media

Prudent Corporate Advisory Services Ltd.(PCAS): Member of NSE & BSE – SEBI Registration No as stock broker: INZ000293634. Member ID : - NSE : 90209, BSE : 6733, CDSL – IN-DP- 477-2020 (DP ID: 12090600), Research Analyst - INH000018115, CIN - L91120GJ2003PLC042458.

Registered Address: Prudent House, Panjrapole Cross Road, Nr. Polytechnic, Ambawadi, Ahmedabad - 380015, Gujarat, India.

For any complaints pertaining to securities / broking please write a mail to [email protected]

Please ensure you carefully read the Risk Disclosure Document as prescribed by SEBI

Investor Alert:
  1. KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (Broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
  2. Prevent Unauthorized transactions in your Trading / Demat account --> Update your mobile numbers/email IDs with us. Receive information of your transactions directly from Exchange / CDSL on your mobile/email at the end of the day / same day.......... Issued in the interest of investors.
  3. No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in the investor's account.
  4. Investors should be cautious on unsolicited emails and SMS advising to buy, sell or hold securities and trade only on the basis of informed decision. Investors are advised to invest after conducting appropriate analysis of respective companies and not to blindly follow unfounded rumours, tips etc. Further, you are also requested to share your knowledge or evidence of systemic wrongdoing, potential frauds or unethical behaviour through the anonymous portal facility provided on BSE & NSE website.
  5. Filing complaints on SCORES – Easy & quick
    • a. Register on SCORES portal b. Mandatory details for filing complaints on SCORES: Name, PAN, Address, Mobile Number, E-mail ID. c. Benefits: i. Effective communication. ii.Speedy redressal of the grievances.
  6. SEBI COMPLAINTS REDRESS SYSTEM Link :- https://scores.gov.in/scores/Welcome.html
  • Attention Investor:
  • 1. Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 1, 2020. 2. Update your mobile number & email Id with your stock broker/depository participant and receive OTP directly from depository on your email id and/or mobile number to create pledge. 3. Pay 20% upfront margin of the transaction value to trade in cash market segment. 4. Investors may please refer to the NSE's Frequently Asked Questions (FAQs) issued vide circular reference NSE/INSP/45191 dated July 31, 2020 and NSE/INSP/45534 dated August 31, 2020 & BSE’s notice no. 20200731-7 dated July 31, 2020 and 20200831-45 dated August 31, 2020 and other guidelines issued from time to time in this regard. 5. Check your Securities /MF/ Bonds in the consolidated account statement issued by NSDL/CDSL every month. .......... Issued in the interest of Investors

Company does not offer any scheme for any assured returns. In case, any such scheme offered by any of employee or other Authorized Person of the company, the same should not be accepted and no investment in such scheme to be made. In case of any such scheme offered by any person, kindly contact compliance team of the company on (+91) (79) 40209600. In case any investment made in such scheme, company will not be responsible for any claims or grievances for any loss on account of relying on the said scheme. 

Advertisement Disclosure - Non-Broking Products/Services e.g. Mutual Fund, Mutual Fund-SIP, Research reports, Insurance, etc "These are not Exchange traded product and the Member is just acting as distributor and all disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism.”